Anavex Life Sciences Corp (AVXL)

[nidan7500]

[quoteNow what
Gilead Sciences dominates HIV and hepatitis C treatment, and this acquisition provides a platform it can use to try to become a top-tier player in oncology. In addition to CAR-T, Kite Pharma is developing T-cell receptor (TCR) technology that may provide a second platform that Gilead Sciences can use to develop treatments for solid tumor cancers, including non-small cell lung cancer.][/quote]

combination products will be a logical medical follow up with the added benefit of accelerated trail/approval cycles due to known variables. A2-73 -AVXL platform is massive by inference.